American Depositary Shares, each representing 80,000 Ordinary Shares
- Symbol
- AKTX
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Akari Therapeutics Plc
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 13, 2026, Akari Therapeutics, Plc. (the “Company”) issued a press release announcing its financial results for the first half of the year ending December 31, 2026 and certain other information. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.…
Company context
We are an oncology company developing next-generation antibody-drug conjugates, or ADCs, designed around novel proprietary cancer-killing toxins, or payloads. We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
Current securities
Registered securities in this filing
Akari Therapeutics, Plc · 8-K · Filed 2026-08-13
Ordinary Shares, par value $0.000000005 per share*
- Symbol
- Not supplied
- Exchange
- Not supplied
- Classification
- COMMON
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
August 13, 2026, Akari Therapeutics, Plc. (the “Company”) issued a press release announcing its financial results
for the first half of the year ending December 31, 2026 and certain other information. A copy of the press release is being furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
The
information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall
it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission
under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general
incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by
law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors TAMPA, FL and LONDON - August 13, 2026 - Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel payload targeting RNA splicing, reported financial results for the second quarter ending June 30, 2026 and provided an update on the continued advancement of its lead ADC candidate, AKTX-101, towards Phase 1 clinical trials. “Akari entered the second half of 2026 with increasing momentum acros…
Open exhibit ↗